Amgen quarterly income rises 6%, revenue beats Avenue estimates By Reuters


© Reuters. FILE PHOTO: An Amgen signal is seen on the firm’s workplace in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Picture

By Deena Beasley

(Reuters) -Amgen, which is dealing with U.S. Federal Commerce Fee (FTC) delays to its deliberate acquisition of Horizon Therapeutics (NASDAQ:), on Thursday reported greater quarterly revenue on sturdy gross sales of therapies for ldl cholesterol, osteoporosis and different medication.

The biotech firm, which barely raised its outlook for full-year income and revenue, stated it at the moment expects the Horizon deal to shut by mid-December.

For the second quarter, Amgen (NASDAQ:) reported income of $6.99 billion, up 6% from a 12 months earlier, exceeding analysts’ estimates of $6.68 billion, in keeping with Refinitiv information.

Earnings, excluding gadgets, rose 8% to $5.00 per share, forward of analyst estimates of $4.46 per share.

Product gross sales by quantity grew 11% from a 12 months earlier, however internet promoting costs fell 2%, whereas overseas trade charges and decrease stock ranges additionally restricted income features, Amgen stated.

“We had 9 merchandise with report gross sales within the quarter,” Amgen Chief Monetary Officer Peter Griffith stated in a cellphone interview.

Quarterly gross sales of ldl cholesterol drug Repatha totaled $424 million, beating the common analyst estimate of $372 million, whereas gross sales of osteoporosis drug Prolia reached $1.03 billion, in contrast with the $954 million analysts had forecast.

The outcomes present some “bounce again” after a difficult first quarter that had raised investor fears a couple of slowdown in Amgen’s base enterprise, Jefferies analyst Michael Yee stated in a analysis observe.

Gross sales of Amjevita, Amgen’s biosimilar model of AbbVie (NYSE:)’s blockbuster arthritis drug Humira, totaled $150 million, wanting Wall Avenue expectations of $204 million.

Amgen stated U.S. Amjevita gross sales fell 63% from the primary quarter, pushed by a drawdown in stock ranges, whereas gross sales exterior of the U.S. rose 13% from a 12 months earlier.

The California-based firm additionally reported optimistic outcomes from a mid-stage trial of experimental drug tarlatamab in sufferers with superior lung most cancers. Amgen stated it’s discussing with regulators whether or not the information may very well be used to hunt approval of the drug for sufferers with relapsed or refractory illness.

For the total 12 months, Amgen modestly raised its outlook for adjusted earnings per share to a spread of $17.80 to $18.80 from its prior forecast of $17.40 to $18.60. The corporate additionally elevated its outlook for 2023 income to $26.6 billion to $27.4 billion from $26 billion to $27.2 billion.

Amgen stated the forecast doesn’t embrace any influence from the deliberate Horizon acquisition.

In a lawsuit, the FTC stated it believed Amgen may leverage its large promoting medication to strain insurance coverage corporations and pharmacy profit managers to favor Horizon’s two key merchandise – thyroid eye illness remedy Tepezza and gout drug Krystexxa – over potential opponents.

“We stay up for making our case in court docket in September,” the CFO stated.

Amgen shares have been up about half a share level at $232 after hours.



Source link

Related articles

U.S. Home passes Trump’s tax invoice in transfer that reverses a lot of Biden’s clear power push

Erik Wasson, Steven T. Dennis and Maeve Sheehey, Bloomberg ...

Is This the Best Method to Make Netflix Really feel Model-New Once more?

In the event you've been feeling currently like Netflix is extra of a chore than a supply of leisure, you are not alone. The homepage is likely to be full of new releases, but...

Bitcoin Close to Historic Weekly Shut – Analyst Warns Of Volatility

Because the market sees a Friday retrace, Bitcoin (BTC) is making an attempt to reclaim an important space as assist. An analyst means that the flagship crypto’s each day shut might set the...

PCA Pairs Dealer Professional — Skilled Advisor Parameters – Buying and selling Methods – 5 July 2025

Easy Technique to Discover the “Proper” 5 Shares for PCA Pairs Dealer Professional Open https://finviz.com/map.ashx?t=sec Hover over a inventory sector....

Prop Agency Funded Unicorn’s A-E-book Wager Ends in Failure, Is FxPro Coming into Crypto Subsequent?

Unraveling of the prop agency Funded UnicornHow far-reaching are the implications of failure in danger dealing with for prop buying and selling companies? The closure of Funded Unicorn, considered one of Germany's high...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com